TABLE 1

ECL	CB1	CB2	GPR18	GPR55	GPR119	TRPV1	PPAR	PPAR/	PPAR
ODA	+1
PEA	+2,3	+2,3		++4	++5	+	++6,7		+8
OEA	+9	+9		++4	+++5	++10	++11,7	++11	+11
AEA	++12,13,14	++12,13		++4	+5	++15	++7		++8
NAGly	+3	+16	+++17			+18
NADA	++19					+++15
2AG	+++14	+++20		++4
Noladin	++14	+21		++4			++7
Virodhamine	-22	++22		+++4			++7

 Ligand activity at cannabinoid or cannabinoid-like receptors from three of the four superfamilies (7-transmembrane, transmitter-gated channels and nuclear receptors) of receptor: there is, as yet, no evidence for ECL activation of catalytic receptors. Scale within the target: - antagonist; + weak/no activity; ++ intermediate; +++ high relative activity; a blank space indicates the activity of the ligand has not been described. Indicated are five 7-transmembrane receptors (CB₁, CB2, GPR18, GPR55 and GPR119), one transmitter-gated channel (TRPV1) and three nuclear receptors (PPAR, PPAR/ and PPAR).

  ¹ Leggett et al. (2004); ² Vandevoorde et al. (2003); ³ Sheskin et al. (1997); ⁴ Drmota et al. ( 2004); ⁵ Overton et al. (2006); ⁶ Lo Verme et al. (2005); ⁷ Sun et al. (2006); ⁸ Bouaboula et al. (2005); ⁹ Lin et al. (1998); ¹⁰ Movahed et al. (2005); ¹¹ Fu et al. (2003); ¹² Felder et al. (1995); ¹³ Slipetz et al. (1995); ¹⁴ Sugiura et al. (1999); ¹⁵ Huang et al. (2002); ¹⁶ Sipe et al. (2005); ¹⁷ Kohno et al. (2006); ¹⁸ Huang et al. (2001b); ¹⁹ Bisogno et al. (2000); ²⁰ Mechoulam et al., 1995; ²¹ Hanus et al., 2001; ²² Porter et al., 2002.